A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer

Lung Cancer

Volumn 46, Issue 1, 2004, Pages 119-124

  Ariganello, Ottavio ^a   Mancuso, Andrea ^a   Di Molfetta, Michele ^a   Diana, Francesco ^a   Beccaglia, Patrizia ^c   Cortesi, Enrico ^b,d   De Marinis, Filippo ^a,d  

^a 5th Pneumo Oncology Unit   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Medical Department   (Italy)

^d Foundation on Cancer Research   (Italy)

Author keywords

Anemia; Dose intensity; Epoetin alfa 40.000 IU; Lung cancer; New regimens; Platinum salts; RBC transfusion

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; HEMOGLOBIN; NAVELBINE; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL ANALYSIS;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 4444291043     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.03.017     Document Type: Article

References (27)

1. DeVita VTJ, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 6th ed. Philadelphia: J.B. Lippincott Co., 2001.
2. Non-small Cell Lung Cancer Collaborative Group: chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev, Jan 2000.
3. Winn R.J., Brown N.H., Botnick W.Z. Reproducibility of guidelines. A comparison of the NCCN and ASCO lung cancer guidelines. Oncology (Huntingt). 13:1999;35-39
4. Klastersky J., Paesmans M. Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer. 34:2001;S95-S101
5. Groopman J.E., Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. 91(19):1999;1616-1634
6. Ludwig H., Strasser K. Symptomatology of anemia. Semin Oncol. 28(S8):2001;7-14
7. Glaspy J., Degos L., Dicato M., Demetri G.D. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and non platinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist. 7:2002;126-135
8. Caro J.J., Salas M., Ward A., Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer. 91:2001;2214-2221
9. Dunst J. The use of epoetin alfa to increase and maintain hemoglobin levels during radiotherapy. Semin Oncol. 28(S8):2001;42-48
10. Fein D.A., Lee W.R., Hanlon A., Ridge J.A., Langer C.J., Curran W.J. Jr., et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J. Clin. Oncol. 13:1995;2077-2083
11. Glaser C.M., Millesi W., Kornek G.V., Lang S., Schull B., Watzinger F. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat Oncol Biol. Phys. 50:2001;705-715
12. Thomas G. The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin. Oncol. 28(S8):2001;60-65
13. Mancuso A., Beccaglia P., De Marinis F. Radiochemotherapy-associated anemia and survival: an analysis of published studies. Ann Oncol. 14(S4):2003;iv59
14. Barrett-Lee P.J., Bailey N.P., O'Brien M.E.R., et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br. J. Cancer. 82:2000;93-97
15. Cheung W., Minton N., Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur. J. Clin. Pharmacol. 57:2001;411-418
16. Abels R.I. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol. 87(S1):1992;4-11
17. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J. Clin. Oncol. 15:1997;1218-1234
18. Demetri G.D., Kris M., Wade J., Degos L., Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J. Clin. Oncol. 16:1998;3412-3425
19. Gabrilove J.L., Cleeland C.S., Livingston R.B., Sarokhan B., Winer E., Einhorn L.H. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. 19:2001;2875-2882
20. Littlewood T.J., Bajetta E., Nortier J.W.R., Vercammen E., Rapoport B. Epoetin Alfa Study Group Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19:2001;2865-2874
21. Rizzo J.D., Lichtin A.E., Woolf S.H., Seidenfeld J., Bennett C.L., Cella D., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin. Oncol. 20:2002;4083-4107
22. Rizzo J.D., Lichtin A.E., Woolf S.H., Seidenfeld J., Bennett C.L., Cella D., et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 100:2002;2303-2320
23. Cheung W.K., Goon B.L., Guilfoyle M.C., Wacholtz M.C. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin. Pharmacol. Ther. 64:1998;412-423
24. Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D., Spivak J.L. Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. 322:1990;1689-1692
25. Italian Fatigue-QOL/MDS Cooperative Group. Effects of bi-weekly dosing of epoetin alfa on fatigue/QOL and anemia in low-risk myelodysplastic syndrome (MDS) patients: results at 8 weeks of treatment. Hematol J 2002;3:66 (abstr. 0187).
26. Scaramucci L., Bongarzoni V., Niscola P. Effects of high-dose alpha-epoetin (HD alpha-epo) on anaemia in advanced multiple myeloma (MM) patients. Hematol J. 3:2002;418. (abstr. 1449)
27. Cortesi E, Mancuso A, De Pasquale Ceratti A, De Marinis F, Beccaglia P, Bertelletti D. Effectiveness and safety of a induction therapy with epoetin alfa in anemic patients receiving concomitant chemotherapy. The Oncologist, in press.